| 1. |
- Chatterjee, Samir, et al.
(författare)
-
Information Systems Research: Making an Impact in a Publish-or-Perish World
- 2018
-
Ingår i: Communications of the Association for Information Systems. - : Association for Information Systems. - 1529-3181. ; 43:1, s. 466-481
-
Tidskriftsartikel (refereegranskat)abstract
- This paper reports on the panel discussion that took place at the European Conference on Information Systems (ECIS) in Guimarães, Portugal, on 9 June, 2017. The discussion focused on three central questions: 1) “What does research impact mean for you?”, 2) “What is your approach to making an impact with your research?”, and 3) “What advice would you give to PhD students and early-career scholars?”. While the five panelists (Samir Chatterjee, Alan R. Dennis, Shirley Gregor, Magnus Mähring, and Peter Mertens) partly differed in their views on what impactful research is and how to conduct it, they seemed to largely agree that assessing impact requires a multidimensional view, that impactful IS research requires a clear link to real-world problems (“grand challenges”), and that young scholars need to avoid the trap of confusing research gaps with research relevance. With the panel discussion and this report, we hope to initiate a discussion on the essential topic of research impact in the IS discipline and to contribute to the development of a more uniform, yet more diverse, understanding and appreciation of different approaches to making an impact with IS research.
|
|
| 2. |
- Lener, Thomas, et al.
(författare)
-
Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.
- 2015
-
Ingår i: Journal of extracellular vesicles. - : Wiley. - 2001-3078. ; 4
-
Tidskriftsartikel (refereegranskat)abstract
- Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV-based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD), summarize recent developments and the current knowledge of EV-based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.
|
|
